SCHEMBL3249205

SCHEMBL3249205

COC(=O)C(CO)NC(=O)NC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.60
EPHX2 P34913 2/20 0.48
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
ALDH1A1 P00352 5/20 0.45
MAPT P10636 5/20 0.45
MAPK1 P28482 5/20 0.45
NPSR1 Q6W5P4 5/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
POLB P06746 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
GPR55 Q9Y2T6 1/20 0.42
YAP1 P46937 1/20 0.42
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249206 1.00 EPHX1 (0.60) EPHX1EPHX2CA12CA1CA2
SCHEMBL27693907 0.89 EPHX1 (0.61) EPHX1EPHX2CA12CA1CA2
SCHEMBL27693908 0.89 EPHX1 (0.61) EPHX1EPHX2CA12CA1CA2
SCHEMBL3859779 0.85 EPHX1 (0.44) EPHX1EPHX2CA12CA1CA2
SCHEMBL2585461 0.84 PTPN2 (0.49) EPHX1MAPK1MEN1KMT2ANPC1
SCHEMBL3248424 0.82 EPHX1 (0.61) EPHX1EPHX2CA12CA1CA2
SCHEMBL3248423 0.82 EPHX1 (0.61) EPHX1EPHX2CA12CA1CA2
SCHEMBL30759724 0.81 YAP1 (0.42) EPHX1ALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL30759763 0.80 YAP1 (0.46) EPHX1ALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL15864150 0.78 YAP1 (0.46) EPHX1ALDH1A1YAP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856100-B1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2010-05-05 EP disclosed
US-7632832-B2 CGRP receptor antagonists MERCK & CO., INC. (US) 2009-12-15 US disclosed
EP-1856100-A4 CGRP RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2009-04-15 EP disclosed
US-20080125413-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-05-29 US disclosed
EP-1856100-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-11-21 EP disclosed
WO-2006078554-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125413-A1 Cgrp Receptor Antagonists CALCRL, NPY1R, CCKBR EPHX1 1540/4885EPHX2 2396/4885CA12 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.